BAMCO Africa
- Company typePrivate
- Founded2023
- HeadquartersKigali, Rwanda
- Headcount1–10
- GTM typeB2B
- OfferingServices
BAMCO Africa firmographics
Firmographics- Name
- BAMCO Africa
- Legal name
- BAMCO AFRICA, INC
- Website
- https://bamcoafrica.com
- Company type
- Private
- Founded year
- 2023
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
BAMCO Africa industry classification
Industry- Product category
- Healthcare Market Access Services
- NAICS
- Other Management Consulting Services (541618)
- SIC
- Services-Misc Health & Allied Services, Nec (8090)
- akta.pro primary industry
- Regulatory Strategy & IND/NDA/BLA Submissions Support (HLAIALAH)
Keywords
Where BAMCO Africa is headquartered
LocationHeadquarters
- HQ city
- Kigali
- HQ country
- Rwanda
- HQ region
- Africa
Offices3 records
Markets served
BAMCO Africa business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure
Revenue model
- Strategic Partnerships and Access Solutions: BAMCO Africa generates revenue through collaborating with pharmaceutical and biotechnology companies to introduce and expand access to standard-of-care treatments in Sub-Saharan Africa. They facilitate partnerships with public and private payers to increase the availability of essential medicines, offering regulatory, commercial, and distribution support for a fee or revenue share arrangement.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
BAMCO Africa product offering
Product offeringCore offering
BAMCO Africa is a Business Development, Access, Medical, and Clinical Operations healthcare company that facilitates patient access to innovative therapies in Sub-Saharan Africa, with focus on oncology and cardio-metabolic diseases. The company provides strategic partnerships with pharmaceutical and biotechnology firms, supports regulatory approval and commercialization, drives access to medicines through payer partnerships, delivers medical education, and organizes clinical trial operations across the region.
Product overview
BAMCO Africa is a Business Development, Access, Medical, and Clinical Operations (BAMCO) healthcare company focused on providing access to innovative therapies for patients in Sub-Saharan Africa. The company operates a portfolio of interconnected service offerings including Strategic Partnerships (collaborating with pharmaceutical and biotechnology companies), Access to Medicines (facility partnerships with payers), Regulatory & Commercial Support, Medical Education, and Clinical Trials. In June 2025, BAMCO launched its first branded pharmaceutical product, Brenzavvy® (bexagliflozin) 20mg, an oral Type 2 Diabetes medication developed in partnership with TheracosBio. The company prioritizes oncology and cardio-metabolic diseases and works closely with governments across select Sub-Saharan African countries.
Differentiator
Problem solved
Functional benefit
Products and services
- Brenzavvy (bexagliflozin) 20mg Bexagliflozin 20mg tablet; first product launched in Rwanda through partnership with TheracosBio for treatment of cardio-metabolic diseases in Sub-Saharan African patients.
- Strategic Partnerships Business development service that forges strategic alliances between international pharmaceutical/biotech innovators and Sub-Saharan African healthcare systems to bring novel therapies to the region.
- Access to Medicines Service that works with payers and healthcare providers to enable patient access to innovative therapies, particularly in oncology and cardio-metabolic disease areas.
- Regulatory and Commercial Support Service that supports regulatory approval pathways and commercialization strategies for pharmaceutical products entering Sub-Saharan African markets.
- Medical Education Educational programs that train healthcare professionals in Sub-Saharan Africa on oncology and cardio-metabolic disease management and novel therapies.
- Clinical Trial Operations Clinical research services that organize and manage clinical trials across Sub-Saharan Africa for sponsor pharmaceutical and biotechnology companies.
Quantifiable outcome
- Brenzavvy (bexagliflozin) 20mg launched in Rwanda within two years of FDA approval - demonstrating ability to accelerate access to innovative treatments in SSA
Companies that use BAMCO Africa
Customer profileSegments1 record
Ideal customer profiles2 records
BAMCO Africa technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
BAMCO Africa partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- TheracosBiocoreBAMCO Africa partnered with TheracosBio to bring affordably priced diabetes medication (Brenzavvy/bexagliflozin) to Sub-Saharan Africa. This landmark collaboration aims to make affordable diabetes treatment accessible to millions of patients across the region, addressing significant barriers to diabetes management due to high costs and limited resources. The partnership launched Brenzavvy in Rwanda in June 2025, within two years of FDA approval.
Scale indicators2 records
Recent moves5 records
Expansion highlights4 records
BAMCO Africa competitors and assessment
Company assessmentMarket position
Competitive moat3 records
Key highlights6 records
Customer concentration
BAMCO Africa social profiles
Digital presenceBAMCO Africa financial estimates
Financial estimateRevenue estimate
Valuation estimate
BAMCO Africa leadership team
Management profileNumber of profiles
Profiles9 records
BAMCO Africa subsidiaries and ownership
Company hierarchySubsidiaries2 records
BAMCO Africa funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
BAMCO Africa M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about BAMCO Africa
What does BAMCO Africa do?
BAMCO Africa is a Business Development, Access, Medical, and Clinical Operations healthcare company that facilitates patient access to innovative therapies in Sub-Saharan Africa, with focus on oncology and cardio-metabolic diseases. The company provides strategic partnerships with pharmaceutical and biotechnology firms, supports regulatory approval and commercialization, drives access to medicines through payer partnerships, delivers medical education, and organizes clinical trial operations across the region.
Is BAMCO Africa a public or private company?
BAMCO Africa is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was BAMCO Africa founded?
BAMCO Africa was founded in 2023. It employs 1 to 10 people.
Where is BAMCO Africa based?
BAMCO Africa is headquartered in Kigali, Rwanda, in the Africa region.
How does BAMCO Africa make money?
One revenue line is on record: strategic Partnerships and Access Solutions.
Does BAMCO Africa have an API?
No public API is recorded for BAMCO Africa.
What industry is BAMCO Africa in?
BAMCO Africa's product category is Healthcare Market Access Services. Its primary akta.pro industry code is HLAIALAH, Regulatory Strategy & IND/NDA/BLA Submissions Support. Its NAICS code is 541618 and its SIC code is 8090.